live attenuated influenza vaccine


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.
Related to live attenuated influenza vaccine: FluMist

live attenuated influenza vaccine

Abbreviation: LAIV
A live virus vaccine made with influenza viruses adapted to replicate in the nose, sinuses, and pharynx but not in the lower respiratory tract. LAIV is typically administered by nasal inhalation rather than by intramuscular injection.
See also: vaccine
References in periodicals archive ?
Meta-Analysis of the Efficacy of Live Attenuated Influenza Vaccine (LAIV) in Children 2 Through 17 Years of Age.
MedImmune's live attenuated influenza vaccine (LAIV) technology may be particularly well-suited for vaccinating against emerging influenza strains.
Moreover, Live Attenuated Influenza Vaccine (LAIV) is expected to be more effective in inducing local and cellular immunity and as such may be more efficacious in eliciting protection.
Shedding and Safety of Live Attenuated Influenza Vaccine in Healthy Subjects 6 to <60 Months of Age(1) (Block SL, Reisinger KS)
BDM has three products actively in development within its pipeline including a live attenuated influenza vaccine (LAIV), treatment for the retinal eye diseases, animal feed enhancer to replace antibiotics.
These prioritized recommendations do not pertain to the nasally administered vaccine, live attenuated influenza vaccine (LAIV), which can be administered at any time for vaccination of non-pregnant healthy persons aged 5-49 years, including most health care personnel and persons in close contact with high-risk groups.
at the Mount Sinai School of Medicine on the development of microRNA-based attenuated influenza viruses which offer the potential for use as improved live attenuated influenza vaccines.
Vivaldi), a biotechnology company focused on development of vaccines for influenza, today announced that the United States Patent and Trademark Office has issued US Patent 7,588,768 covering live attenuated influenza vaccines (LAIVs) with modifications to the viral NS1 gene, and methods for producing the vaccines in cell culture systems.
Further, no studies have been published that compare the cost-effectiveness of live attenuated influenza vaccines with that of inactivated influenza vaccines.